OXiGENE launches significant expansion of its R&D program in ophthalmology
Waltham, Mass., December 10, 2003 OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced a significant expansion of its research and development program in ophthalmology, including plans to begin human studies in several retinal degenerative indications and to develop formulations of its lead vascular targeting agent, Combretastatin A4 Prodrug (CA4P), for local delivery to the eye....... OXiGE...OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
Watertown, Massachusetts, July 2, 2003 OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that The Johns Hopkins University School of Medicine will begin a Phase I/II clinical trial of the Company's lead vascular targeting agent, Combretastatin A4 Prodrug (CA4P). The study will be conducted in patients with a retinal degenerative disease known as wet age-related macular degeneration (AMD)...OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
WATERTOWN, Mass.-- Jan. 7, 2003-- OXiGENE, Inc. (Nasdaq: OXGN, SSE: OXGN) today announced the initiation of a Phase I/II combination study of its lead vascular targeting agent (VTA), Combretastatin A4 Prodrug (CA4P), in patients with advanced cancer of the lung, head & neck and prostate. These cancers accounted for an estimated 192,500 deaths in the United States in 2002. CA4P became the first VT...OXiGENE announces phase II clinical trial of lead anti-tumor compound in thyroid cancer
WATERTOWN, Mass--Dec. 23, 2002--... OXiGENE, Inc. (Nasdaq: OXGN, SSE: OXGN), today announced the start...of a Phase II clinical trial for its lead vascular targeting agent...(VTA), a tumor-starving compound called Combretastatin A4 Prodrug...(CA4P), in patients with a rare and often incurable form of thyroid...cancer. OXiGENE is the world's first biopharmaceutical firm whose VTA...has advanced...OXiGENE, foundation fighting blindness sign research agreement for phase I/II clinical trial
WATERTOWN, Mass. (Oct. 31, 2002)-......... OXiGENE, Inc. (Nasdaq: OXGN, SSE: OXGN), in a step that will...significantly advance vision-related research of its lead vascular...targeting compound, Combretastatin A4 Prodrug (CA4P), today announced...the signing of a funded research agreement with The Foundation...Fighting Blindness, Inc. The Foundation is a nationwide charitable...organization wh...